BNF:

10.1.4

Status:

Green

Decision Date:

None

Comments

2nd line for use in patients where allopurinol is contraindicated or not tolerated as per NICE TA 164

MHRA May 2023: Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease

search again